ArticleJNCI cancer spectrum2026
Cancer risk associated with abatacept among older individuals with rheumatoid arthritis in the United States.
Article in JNCI cancer spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundWe sought to examine the association between abatacept therapy and cancer risk among individuals with rheumatoid arthritis (RA).
methodsWe conducted a case-control study of individuals with RA in the United States aged 65-99 years (17 665 patients with cancer and 53 652 control individuals during 2008-2019) using the Surveillance, Epidemiology, and End Results (SEER) Program-Medicare database. For assessing risk of nonmelanoma skin cancer, individuals of White race with RA and nonmelanoma skin cancer and corresponding control individuals were selected from among Medicare beneficiaries residing in SEER areas. Exposure to abatacept, tumor necrosis factor (TNF) inhibitors, and conventional disease-modifying antirheumatic drugs (DMARDs) was ascertained using prescription claims. Individuals exposed to both abatacept and TNF inhibitors were excluded. We calculated adjusted odds ratios (AORs) to measure associations between abatacept (with or without a conventional DMARD) and overall risk of cancer, 17 specific cancer sites, and nonmelanoma skin cancer.
resultsOverall, 2.5% of SEER cancer cases and 2.6% of control individuals were treated with abatacept (with or without a conventional DMARD). Overall cancer risk was not associated with exposure to abatacept compared with a TNF inhibitor (with or without a conventional DMARD) (AOR = 1.03, 95% confidence interval [CI] = 0.88 to 1.21) or with conventional DMARDs only (AOR = 1.02, 95% CI = 0.87 to 1.19). Abatacept was associated with increased nonmelanoma skin cancer risk compared with both TNF inhibitors (with or without a conventional DMARD) (AOR = 1.31, 95% CI = 1.01 to 1.70) and conventional DMARDs only (AOR = 1.31, 95% CI = 1.01 to 1.71). Abatacept was also associated with increased lung cancer risk among individuals with recent-onset RA (AOR = 1.53, 95% CI = 1.01 to 2.32, compared with TNF inhibitors). These associations were not statistically significant after correction for multiple comparisons.
conclusionsAmong older adults with RA, abatacept exposure was not associated with cancer risk overall, but there was some evidence for increased risks of nonmelanoma skin cancer and lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.